Skip to main content

Hensley Mark Earl's Form 4 filing

Heron Therapeutics, Inc. (HRTX) · filed Aug 10, 2026

Accession no.
0001193125-26-341528
Filed
Aug 10, 2026, 10:18 AM ET
Trade date
Aug 6, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hensley Mark EarlCIK 0002065816Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 6, 2026Common StockMOption exerciseAcquired+31,250–F1–179,789Direct
Aug 6, 2026Common StockFTax withholdingDisposed−8,888$0.50−$4,444170,901Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 6, 2026Common StockMOption exerciseDisposed−31,250$0.00$0343,750Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of common stock.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)